PTO Strikes Down Ariad’s Patent

Law360, New York (September 8, 2006, 12:00 AM EDT) -- The U.S. Patent & Trademark Office has invalidated 160 of 203 claims on a patent that is vital to Ariad Pharmaceuticals Inc.’s case against rival Eli Lilly & Co.

Though the PTO’s decision is not final—Ariad still has a chance to reply—it does provide Eli Lilly with a bargaining chip in future negotiations and with powerful evidence in future trials.

In the re-examination, the PTO struck down most of Ariad’s claims for obviousness. When something is old, it does not become patentable just because the scientific...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.